Food and Drug Administration (FDA) officials have proposed a future model for developing new COVID-19 vaccines that would be built on the approach to creating influenza vaccines. Accumulating data suggest the current COVID-19 vaccines, based on a virus strain that is now generations old, “may need to be updated at some point to ensure the high level of efficacy demonstrated in the early vaccine clinical trials,” the FDA said. One concern is how new strains of SARS-CoV-2 keep emerging, some of which bypass protection bestowed by the vaccines better than others. SARS-CoV-2, also known as the CCP (Chinese Communist Party) virus, causes COVID-19. The vaccines provide virtually no protection against infection from Omicron, the strain that is dominant in the United States at present, though they have held up better against severe disease. U.S. regulators say an orderly and transparent process should be outlined for changing the composition of the COVID-19 …